JP2017501172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501172A5 JP2017501172A5 JP2016540693A JP2016540693A JP2017501172A5 JP 2017501172 A5 JP2017501172 A5 JP 2017501172A5 JP 2016540693 A JP2016540693 A JP 2016540693A JP 2016540693 A JP2016540693 A JP 2016540693A JP 2017501172 A5 JP2017501172 A5 JP 2017501172A5
- Authority
- JP
- Japan
- Prior art keywords
- survivin
- seq
- mol
- liposome preparation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005831 | 2013-12-16 | ||
| EP13005831.6 | 2013-12-16 | ||
| PCT/EP2014/003384 WO2015090572A1 (en) | 2013-12-16 | 2014-12-16 | Survivin-directed cancer vaccine therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017501172A JP2017501172A (ja) | 2017-01-12 |
| JP2017501172A5 true JP2017501172A5 (enExample) | 2017-12-28 |
Family
ID=49884863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540693A Pending JP2017501172A (ja) | 2013-12-16 | 2014-12-16 | サバイビン指向性癌ワクチン治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160279213A1 (enExample) |
| EP (1) | EP3083663A1 (enExample) |
| JP (1) | JP2017501172A (enExample) |
| CN (1) | CN105873941A (enExample) |
| AU (1) | AU2014365888B2 (enExample) |
| CA (1) | CA2933705A1 (enExample) |
| IL (1) | IL246299A0 (enExample) |
| WO (1) | WO2015090572A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| MX387323B (es) * | 2014-02-19 | 2025-03-18 | Merck Patent Gmbh | Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer. |
| CN107951861B (zh) * | 2016-10-17 | 2020-12-01 | 南京绿叶制药有限公司 | 一种脂质纳米粒膜材料组合物 |
| KR102069680B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
| CN109125740B (zh) * | 2017-06-28 | 2022-04-05 | 成都威斯克生物医药有限公司 | 一种新型的肿瘤疫苗及其用途 |
| CN109125741B (zh) * | 2018-08-13 | 2022-02-11 | 四川大学 | 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法 |
| CA3117914A1 (en) * | 2018-10-24 | 2020-04-30 | Apa- Advanced Technologies Ltd. | Fusogenic liposomes for selective imaging of tumor cells |
| US20220125903A1 (en) * | 2018-11-19 | 2022-04-28 | Immunovaccine Technologies Inc. | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors |
| CN111983240B (zh) * | 2020-08-27 | 2023-11-21 | 天津大学 | 一种产气荚膜梭菌α毒素可视化检测的方法 |
| JP7318983B2 (ja) * | 2021-12-21 | 2023-08-01 | 株式会社アビー | 細胞凍結保存液、及び細胞凍結方法 |
| CN116617414B (zh) * | 2023-03-31 | 2024-04-05 | 中国农业大学 | 一种脂质体及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE414149T1 (de) * | 1996-11-20 | 2008-11-15 | Univ Yale | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation |
| CN1316037C (zh) * | 2003-12-19 | 2007-05-16 | 叶尚勉 | 检测待测标本中生存素表达量的诊断试剂、检测方法及应用 |
| ES2523172T3 (es) * | 2005-02-04 | 2014-11-21 | Survac Aps | Vacuna de péptido de survivina |
| EP2276495B1 (en) * | 2008-04-17 | 2018-11-21 | PDS Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
-
2014
- 2014-12-16 CN CN201480068752.XA patent/CN105873941A/zh not_active Withdrawn
- 2014-12-16 JP JP2016540693A patent/JP2017501172A/ja active Pending
- 2014-12-16 WO PCT/EP2014/003384 patent/WO2015090572A1/en not_active Ceased
- 2014-12-16 AU AU2014365888A patent/AU2014365888B2/en not_active Expired - Fee Related
- 2014-12-16 EP EP14814776.2A patent/EP3083663A1/en not_active Withdrawn
- 2014-12-16 CA CA2933705A patent/CA2933705A1/en not_active Abandoned
- 2014-12-16 US US15/036,629 patent/US20160279213A1/en not_active Abandoned
-
2016
- 2016-06-16 IL IL246299A patent/IL246299A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501172A5 (enExample) | ||
| Ho et al. | Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? | |
| ES2702622T3 (es) | Método para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer | |
| Vacchelli et al. | Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy | |
| Razazan et al. | Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model | |
| KR102823291B1 (ko) | 종양-관련된 항원 에피토프의 미생물 서열 변이체 | |
| JP2013526837A5 (enExample) | ||
| CN108350411B (zh) | 口服肿瘤疫苗 | |
| Robson et al. | Presentation of tumour antigens by dendritic cells and challenges faced | |
| US20160279213A1 (en) | Survivin-Directed Cancer Vaccine Therapy | |
| CN110049774A (zh) | 肿瘤相关抗原表位的小型生物群序列变体 | |
| CN110621339A (zh) | 疫苗接种 | |
| CN110022894B (zh) | 用于癌症疗法的免疫原性化合物 | |
| JP2010514669A5 (enExample) | ||
| CN110214028A (zh) | 联合使用口服肿瘤疫苗和免疫抑制阻滞剂的癌症治疗 | |
| Shariat et al. | Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects | |
| JP2014506114A5 (enExample) | ||
| US20240033336A1 (en) | Tumor antigens, compounds comprising the tumor antigens and uses thereof | |
| JP2017500305A5 (enExample) | ||
| Hu | Multiple Vaccinations | |
| Yagui-Beltrán et al. | Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines | |
| HK1220914B (en) | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |